Seth J. Baum
171 works · 11,151 citations · h-index 35
Top works
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
- Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- Clinical Genetic Testing for Familial Hypercholesterolemia
- Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
- Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
- Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States
- Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
- Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
- Evinacumab in Patients with Refractory Hypercholesterolemia
- Fatty acids in cardiovascular health and disease: A comprehensive update
- Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
- Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta‐Analysis
- Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
- MR Imaging in the Definition of Coronary Artery Anomalies
- Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
- Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial